News
ONCY
1.045
+1.46%
0.015
Weekly Report: what happened at ONCY last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at ONCY last week (0311-0315)?
Weekly Report · 03/18 10:32
Biotech's Role in Addressing the Pancreatic Cancer Emergency
Pancreatic cancer still has the highest mortality rate of all major cancers. American Cancer Society projecting a record year for new cancer cases in 2024. Researchers and the biotech sector are working diligently to improve the chances of those diagnosed with pancreatic cancer. Researchers at the Mayo Clinic made a discovery that advances knowledge of how the cancer spreads.
Barchart · 03/14 07:45
Weekly Report: what happened at ONCY last week (0304-0308)?
Weekly Report · 03/11 10:30
Buy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment Trials
TipRanks · 03/09 17:25
Buy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical Trials
TipRanks · 03/08 21:25
Oncolytics Biotech Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/08 18:14
Oncolytics Biotech Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 03/08 18:14
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Maintains $5 Price Target
Benzinga · 03/08 18:04
Maintaining Buy Rating on ONCY Amidst Promising Clinical Advancements and Partnership Potential
Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Oncolytics Biotech (ONCY) The company is transitioning to late-stage clinical development with plans to launch studies in breast and pancreatic cancers in 2024. The company’s lead program, pelareorep, is being developed for the treatment of cancer.
TipRanks · 03/08 17:35
Oncolytics Biotech (ONCY) Gets a Buy from RBC Capital
TipRanks · 03/08 12:27
Stocks in play: Oncolytics Biotech Inc
Announced recent operational highlights and financial results for the fourth quarter and year ended December 31, 2023. Pelareorep advancing to a registration-enabling study in pancreatic cancer in 2024. Cash position of $34.9 million provides runway through 2025. Oncolytics Biotech Inc shares are trading unchanged at $1.41.
Barchart · 03/08 08:40
ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q4 2023
Oncolytics Biotech reported earnings per share of -4 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -11 cents. Oncolytic Biotech just reported results.
Investorplace · 03/08 02:55
Oncolytics Biotech Inc reports results for the quarter ended in December - Earnings Summary
Oncolytics Biotech Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 5 cents per share. The mean expectation of six analysts was for a loss of 15 cents. The average analyst rating on the company's shares is "buy"
Reuters · 03/07 23:38
Oncolytics Biotech GAAP EPS of -$0.05 beats by $0.06
Seeking Alpha · 03/07 21:39
Oncolytics Biotech Shows Promising Cancer Drug Progress
TipRanks · 03/07 21:38
Recap: Oncolytics Biotech Q4 Earnings
Oncolytics Biotech reported its Q4 earnings on March 7. The company beat estimates by 64.0%. Oncolytic Biotech's revenue was down $0 from the same period last year. Last quarter the company missed on EPS by $0.0.
Benzinga · 03/07 21:10
Oncolytics Biotech Q4 EPS $(0.04) Beats $(0.11) Estimate
Benzinga · 03/07 21:07
*Oncolytics Biotech 4Q Loss/Shr $0.05 Vs. Loss $0.14 >ONC.T ONCY
Dow Jones · 03/07 21:04
Press Release: Oncolytics Biotech(R) Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Oncolytics Biotech(R) Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights. Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential. Impressive objective response rate in GOBLET study anal carcinoma cohort supports enrollment expansion Expecting to report overall survival data from BRACELET-1 breast cancerStudy in 2024. Cash position of $34.9 million provides runway through critical milestones into 2025.
Dow Jones · 03/07 21:01
More
Webull provides a variety of real-time ONCY stock news. You can receive the latest news about Oncolytics Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About ONCY
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.